Reuters logo
4 个月前
BRIEF-Intelgenx and Redhill Biopharma announce marketing approval of rizaport for migraines
2017年4月13日 / 上午10点08分 / 4 个月前

BRIEF-Intelgenx and Redhill Biopharma announce marketing approval of rizaport for migraines

April 13 (Reuters) - Intelgenx Technologies Corp -

* Intelgenx and Redhill Biopharma announce marketing approval of rizaport(r) for migraines in Luxembourg

* Co, Redhill expect to re-submit rizaport 505(b)(2) new drug application to FDA in q3 of 2017

* Cos are continuing discussions with additional potential commercialization partners for rizaport in U.S. , Europe, other territories Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below